Adverse Event Reporting The Lancet Haematology ++++

https://www.thelancet.com/series-do/adverse-events-in-haemotology-oncology?dgcid=hubspot_update_feature_lanhaeadverseevents25&utm_campaign=update-lanhae&utm_medium=email&_hsenc=p2ANqtz-8xi5dW4bEaGkzvKaJYqGOpcJGIfP4HfI1rSigcsLz12vfPID2sgGuji2zBdFkwCQV6Q-d-cEEyaDLHtIqAkJMkp4evTg&_hsmi=365624288&utm_content=365401806&utm_source=hs_email Executive summary Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Several haematological malignancies are now chronic diseases that are treated with continuously administered therapies that have unique side-effects over time. In 2018, The Lancet Haematology’s Commission Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies was published. In the Commission, an international panel of clinicians, clinical investigators, methodologists, regulators, and patient advocates representing a broad range of academic and clinical cancer expertise examined adverse events in haematological malignancies. Machine-learning models to predict iron recovery after blood donation: a model development and external validation study https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00068-7/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz--KempT28GrY68gcryNSSIyqJOKbH0PhJfXEcSO1JIg4eLtT6aaV-HV-AdAQwcF5ZB7rBHuOz0dVuqFYBWts2aWMil7yA&_hsmi=365624288&utm_content=365401806&utm_source=hs_email Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00081-X/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz--8O2-r1sd_90aeK4ibf_Leql-WgRd8gUjLg7xVnqgU_kCmz7he4nMaArGctf2lFMZjBii2uOIM5Dv3qccqXuptqbSZJQ&_hsmi=365624288&utm_content=365401806&utm_source=hs_email Patients first: improving toxicity assessment and reporting The Lancet Haematology https://www.thelancet.com/journals/lanhae/issue/vol12no6/PIIS2352-3026(25)X0006-5